Organovo Holdings, Inc. (ONVO)

[RandolRocketman]

This is kind of a big deal. Not sure why the price doesn't reflect this reality:
The designation also includes a waiver of certain fees and a seven-year term of market exclusivity upon FDA approval of the orphan drug, and can provide for a more streamlined and cost-effective path through to commercialization.
This is the beginning of the end of the waiting list for transplant organs, and this is under $2 a share. SMH